Nevro Corp. (NYSE:NVRO) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lowered its holdings in shares of Nevro Corp. (NYSE:NVROGet Rating) by 86.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,595 shares of the medical equipment provider’s stock after selling 23,339 shares during the period. SG Americas Securities LLC’s holdings in Nevro were worth $158,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. FourThought Financial LLC grew its holdings in shares of Nevro by 49.1% during the first quarter. FourThought Financial LLC now owns 683 shares of the medical equipment provider’s stock worth $49,000 after buying an additional 225 shares during the last quarter. CWM LLC lifted its position in Nevro by 29.6% during the 1st quarter. CWM LLC now owns 757 shares of the medical equipment provider’s stock worth $55,000 after acquiring an additional 173 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of Nevro by 104.4% in the 1st quarter. Nisa Investment Advisors LLC now owns 920 shares of the medical equipment provider’s stock valued at $67,000 after purchasing an additional 470 shares during the last quarter. Dupont Capital Management Corp increased its holdings in shares of Nevro by 72.4% in the second quarter. Dupont Capital Management Corp now owns 3,354 shares of the medical equipment provider’s stock valued at $147,000 after purchasing an additional 1,409 shares during the period. Finally, Point72 Hong Kong Ltd acquired a new position in shares of Nevro in the first quarter valued at approximately $170,000. 96.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NVRO has been the subject of several recent research reports. JPMorgan Chase & Co. decreased their price target on Nevro from $50.00 to $40.00 and set a “neutral” rating for the company in a report on Thursday, November 3rd. StockNews.com raised shares of Nevro from a “hold” rating to a “buy” rating in a report on Monday, November 7th. Piper Sandler cut their price target on shares of Nevro from $45.00 to $42.00 and set a “neutral” rating for the company in a report on Thursday, November 3rd. Truist Financial reduced their price objective on shares of Nevro to $45.00 in a research report on Friday, July 22nd. Finally, William Blair reissued a “market perform” rating on shares of Nevro in a research note on Wednesday, November 2nd. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $64.50.

Nevro Stock Performance

Shares of NVRO stock opened at $45.91 on Friday. The stock has a fifty day moving average price of $43.10 and a 200 day moving average price of $45.55. The company has a debt-to-equity ratio of 0.57, a quick ratio of 5.82 and a current ratio of 7.05. The stock has a market cap of $1.63 billion, a PE ratio of -139.12 and a beta of 0.75. Nevro Corp. has a 1 year low of $34.70 and a 1 year high of $98.51.

Nevro (NYSE:NVROGet Rating) last released its quarterly earnings results on Wednesday, November 2nd. The medical equipment provider reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.09. The business had revenue of $100.47 million during the quarter, compared to the consensus estimate of $99.08 million. Nevro had a negative return on equity of 40.89% and a negative net margin of 2.01%. Sell-side analysts forecast that Nevro Corp. will post -2.69 earnings per share for the current fiscal year.

Nevro Profile

(Get Rating)

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems.

Further Reading

Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro Corp. (NYSE:NVROGet Rating).

Institutional Ownership by Quarter for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.